| Document |
Document Title |
|
WO/2024/031153A1 |
The present invention relates to compounds comprising a metal chelator and two fragments capable of binding to type 2 somatostatin receptors, compositions thereof and uses thereof in methods of treatment.
|
|
WO/2024/029481A1 |
Provided is an anti-HBV agent comprising a compound represented by formula (I) or a salt thereof. [In the formula, R1 is a phenyl group substituted with a group represented by -CN or R3-NH-CO- and an alkyl group having 1-6 carbon atoms, ...
|
|
WO/2024/022332A1 |
Provided herein are a compound of Formula (I), a pharmaceutical composition comprising said compound, and method of use of the compound or pharmaceutical composition in the diagnosis or treatment of a disease characterized by overexpress...
|
|
WO/2024/025991A1 |
A method is disclosed of detecting a disease associated with pulmonary vascular remodeling in a subject. The method can comprise administering to the subject a compound of Formula I or Formula II. The method can further comprise imaging ...
|
|
WO/2024/023332A1 |
The invention relates to novel silicon-based fluoride acceptor groups (SiFA groups) of the following formulae (Ia, Ib, Ic) as well as to compounds suitable for use in radiopharmacy comprising such groups, wherein R1 and R2 are each a lin...
|
|
WO/2024/021556A1 |
The present invention belongs to the technical field of radiopharmaceutical chemistry. Provided are a radioactive metal complex targeting a prostate specific membrane antigen and a labeling ligand thereof. The general structural formula ...
|
|
WO/2024/026072A1 |
Disclosed are compounds, compositions, and methods useful for imaging and treating tumor cells in a subject. In particular, the compounds have the structure of Formula I is useful in the dislocsed imaging methods : (I). The variables in ...
|
|
WO/2024/017317A1 |
The present invention relates to an HER2 targeting peptide molecule and a use thereof. The HER2 targeting peptide molecule has the following general formulas: X-peptide, X-L-peptide, peptide-X, and peptide-L-X, wherein X represents a mar...
|
|
WO/2024/020077A1 |
Disclosed are compounds, compositions, and methods useful for imaging cells in a subject. In particular, the compound have the structure of Formula (I) is useful in the dislocsed imaging methods:
|
|
WO/2024/019014A1 |
Provided as a precursor of a radioactive halogen-labeled compound is a compound represented by general formula (I) [in the formula, R1 represents a leaving group that can undergo nucleophilic substitution by a halide ion, R2 represents a...
|
|
WO/2024/017165A1 |
A methoxypolyethylene glycol-poly(lactic-co-glycolic acid)-polylysine-based developing porous microsphere, a preparation method, and use. The developing porous microsphere is prepared by performing development transformation on methoxypo...
|
|
WO/2024/016976A1 |
The present invention relates to a FAP-α specific tumor diagnostic imaging agent, in particular, the present invention relates to a compound of formula (I), a FAP-α specific tumor imaging agent formed by coordination of the compound of...
|
|
WO/2024/016071A1 |
The present disclosure relates to prostate specific membrane antigen (PSMA)-targeting compounds of formula (I) or of a salt or a solvate thereof. The PSMA-targeting compounds of the present disclosure can be useful as imaging agents for ...
|
|
WO/2024/013272A1 |
The present invention relates to a high-Z element containing nanoparticles for use in a method of treating a tumor by radiopharmaceutical therapy, in a subject in need thereof, the method comprising a combined administration of an effici...
|
|
WO/2024/015730A2 |
Herein is disclosed amphiphilic small molecules with different hydrophobic and hydrophilic fragments that show high binding affinity to both Aβ plaques and oligomers, and selectively binding Aβ oligomers. These amphiphilic compounds ca...
|
|
WO/2024/015929A2 |
Compositions, methods of synthesis, and methods of use for an imaging agent that preferentially binds to activated VLA4, including, but not limited to a peptide or peptidomimetic ligand radiolabeled for use in PET imaging to identify bon...
|
|
WO/2024/014501A1 |
To provide an antibody or an antigen-binding fragment thereof that is useful in testing for cancer, especially early cancer. An antibody, or an antigen-binding fragment thereof, that includes a heavy chain CDR1 including an amino acid se...
|
|
WO/2024/012157A1 |
Provided are a polypeptide compound, and a complex and use thereof, specifically relating to the technical field of pharmaceutical chemistry. The polypeptide compound is shown as formula I. Compared with the prior art, the provided pepto...
|
|
WO/2024/008075A1 |
Provided are a preparation method for a liquid composition containing compound I and a use in myocardial perfusion PET imaging, the method comprising the following step: purifying a crude product containing the compound I by using high-p...
|
|
WO/2024/008755A1 |
The present invention relates to binding agents specifically binding to the folate transport complex. More specifically, antibodies or antibody fragments including immunoglobulin single variable domain (ISVD) antibodies are disclosed tha...
|
|
WO/2024/008073A1 |
The present application provides a liquid composition of compound I, a preparation method therefor, and an application thereof, wherein same is selected from one or more among vitamin C, sodium ascorbate, and gentisic acid. By optimizing...
|
|
WO/2024/007034A2 |
Dendrimers radiolabeled with an alpha particle emitter, such as actinium-225 (225Ac), and their use for treating tumors, including glioblastomas, are disclosed.
|
|
WO/2024/003389A1 |
The present invention relates to an anti-mGLUR2 biparatopic nanobody comprising : (i) one single domain antibody having a CDR1 having a sequence set forth as SEQ ID NO:1, a CDR2 having a sequence set forth as SEQ ID NO:2and a CDR3 having...
|
|
WO/2024/003390A1 |
The present invention relates to a polypeptide comprising at least one single domain antibody directed against mGluR2 for use as a biomolecule transporter crossing the blood- brain barrier (BBB), with the proviso that the polypeptide doe...
|
|
WO/2024/002853A1 |
A precursor compound and radiotracer for targeting fibroblast activation protein comprise a chelator Ch and ligand TV with Ch = (Formula) with R = | ‒CH3 or |‒CH2COOH; and TV = (Formula).
|
|
WO/2024/006582A1 |
Compositions for identifying a pathogenic bacterial infection include a mannitol compound with one or more substituents including radioisotopes. These radiopharmaceuticals, such as a positron- emitting mannitol analogue, [18F]fluoromanni...
|
|
WO/2024/001967A1 |
The present invention relates to the technical field of radiopharmaceutical chemistry and clinical nuclear medicine, and in particular, to an imidazonaphthyridine compound with affinity with a Tau protein, a method for preparing same, an...
|
|
WO/2023/245852A1 |
Provided are a CD25 targeting polypeptide, a molecular probe and use. An amino acid sequence of the polypeptide is as follows: i) X1X2X3X4X5; or ii) an amino acid sequence formed by connecting a label at an N-terminus or a C-terminus of ...
|
|
WO/2023/246829A1 |
A liquid composition comprising trans-2-(2-(5-(fluoro[ 18F])tridecyl)cyclopropyl)acetic acid, a preparation method therefor and use thereof in the preparation of a contrast agent for myocardial metabolic PET imaging. The liquid compositi...
|
|
WO/2023/250116A1 |
The present disclosure provides compounds of Formula (I) and (I´), which are derivatives of indocyanine green (ICG), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, and prodr...
|
|
WO/2023/250377A2 |
The present invention provides compositions. The composition comprises micelles having an outer shell comprising one or more polymer-flavonoid conjugates, optionally an inner shell comprising one or more flavonoid oligomer, and a diagnos...
|
|
WO/2023/246830A1 |
The present application provides a method for preparing a myocardial metabolism PET imaging agent, a liquid composition of trans-2-(2-(5-fluoro[18F]tridecyl)cyclopropyl)acetic acid (compound I for short), and use thereof, wherein a crude...
|
|
WO/2023/244828A1 |
A conjugate comprising FL-L-IA, wherein FL is a radical of a ligand that specifically binds with fibroblast activation protein (FAP), L is a linker, which binds an FL to IA, and IA is a nanoparticle-based magnetic resonance imaging (MRI)...
|
|
WO/2023/240342A1 |
A system for obtaining imaging information, diagnosis and treatment of a subject using magneto- aerotactic-responsive bacteria; it has a processor; and memory storing program code that, when executed by the processor, cause the processor...
|
|
WO/2023/245093A1 |
The disclosure is directed in part to polymerizable biocompatible or bioabsorbable compositions comprising styrene, N-vinylpyrrolidone or acrylate monomers, further comprising epoxide, urethane, polyether, or polyester oligomers and free...
|
|
WO/2023/239903A1 |
A method of inhibiting accumulation and/or retention of a prostate-specific membrane antigen (PSMA)-targeted therapy to a non-cancer tissue in a subject includes administering to a subject being treated with the PSMA-targeted therapy a p...
|
|
WO/2023/239953A2 |
The present disclosure is directed in part to methods of imaging a subject's lung, including but not limited to the purpose of evaluating a pulmonary infection in a subject. The method includes administering an imaging agent comprising a...
|
|
WO/2023/235933A1 |
The invention relates to methods and compositions for use in combination radioimmunotherapy.
|
|
WO/2023/239866A1 |
Provided herein are methods of identifying a subject as having a central nervous system (CNS) cancer that include (a) obtaining a DNA sample from the subject; (b) analyzing a plurality of chromosomal sequences in the DNA sample; (c) dete...
|
|
WO/2023/236778A1 |
The present invention relates to a trifunctional compound, comprising at least one covalent warhead capable of forming a reversible or irreversible covalent linkage with a protein or tissue. The present invention further relates to a pha...
|
|
WO/2023/235985A1 |
The present application relates to zwitterion compounds of Formula I, to processes of their preparations, to conjugates thereof, to compositions comprising them and to their use in diagnostics and/or therapy. wherein Q is selected from Q...
|
|
WO/2023/240135A2 |
Provided are new bifunctional chelators for use in the manufacture of radiolabeled targeting agents for therapeutic or diagnostic use. Also provided are conjugates of the new bifunctional chelators with various cancer antigen targeting a...
|
|
WO/2023/235925A1 |
The present invention provides compounds of Formula (I), which have activity as inhibitors of MERTK. The present invention also provides radio-labelled compounds which may be used in diagnostic and imaging compositions. The present inven...
|
|
WO/2023/237092A1 |
Provided are a device for producing a liquid composition of trans-2-[2-(5-[18F]fluorotridecyl)cyclopropyl]acetic acid (compound I), a preparation method therefor and use thereof. In particular, the production device comprises: a pretreat...
|
|
WO/2023/236978A1 |
A device for producing a liquid composition of trans-2-[2-(5-[18F]fluorotridecyl)cyclopropyl]acetic acid (hereinafter referred to as "compound I"), comprising: a pretreatment module, configured to enrich 18F ions; a reaction module, conf...
|
|
WO/2023/239814A1 |
A genetically engineered Escherichia coli Nissle 1917 bacterium is provided. The genetically engineered bacterium comprises an overexpressed number of FyuA receptors. In one embodiment, the genetically engineered bacterium comprises the ...
|
|
WO/2023/238133A2 |
A system for detecting blood in a gastrointestinal tract of a user, including a capsule that is configured to be swallowed by the user and traverse the gastrointestinal tract of the user, a receiver that is configured to be positioned on...
|
|
WO/2023/231452A1 |
The present invention belongs to the technical field of radiopharmaceuticals and medical images. Disclosed in the present invention are a PSMA-targeting radioactive metal complex containing a nitro aromatic heterocyclic group and the pre...
|
|
WO/2023/235772A2 |
Novel chimeric and/or humanized forms of the anti-CD45 BC8 antibody are described. The disclosed chimeric or humanized antibodies can be used as research, diagnostic, or therapeutic tools against CD45-related disorders, such as hematolog...
|
|
WO/2023/233023A1 |
The current invention relates to a compound of Formula (I) or a stereoisomer, tautomer, racemic, metabolite, prodrug, salt, hydrate, or solvate thereof, The invention also relates to a pharmaceutical composition comprising said compound....
|
